Author

Joachim Albers

Merck KGaA, Darmstadt (Germany)ORCID 0000-0003-0582-1863Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

Alan D. D’AndreaiD· 1 shared Astrid ZimmermanniD· 1 shared Aurélie QuintiniD· 1 shared Bose S. KochupurakkaliD· 1 shared Daniel M. AebersoldiD· 1 shared Geoffrey Ira ShapiroiD· 1 shared Gregory Michael CoteiD· 1 shared Ian A. RoundtreeiD· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alan D. D’AndreaORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintOct 28, 2026

DNA-PK enforces the S/G2 checkpoint in ATM-deficient cells to limit ATR inhibitor efficacy

Timothy B. Branigan, Roshen Alharthi, Bose S. Kochupurakkal…·Geoffrey Ira Shapiro

This study shows DNA-PK enforces the S/G2 checkpoint in ATM-deficient cells, reducing ATR inhibitor efficacy, and suggests combining ATR and DNA-PK inhibition could enhance treatment in such cancers.

DOI 10.64898/2026.10.25.761677

humanexperimental assay

𝕏 PostBluesky

Cancer BiologyMolecular Cancer TherapeuticsPeer-reviewedNov 8, 2024

HPV and p53 status as precision determinants of head and neck cancer response to DNA-PKcs inhibition in combination with irradiation

Liana Hayrapetyan, Selina M. Roth, Aurélie Quintin…·Michaela Medová

12 citationstop 5%

humanexperimental assay

𝕏 PostBluesky